Novo Nordisk (NVO) Raises Annual Outlook on $11.9B Q3 Sales Beat
Published on · Source: cnbc.com
AI Summary
Summarized by AI from the source belowNovo Nordisk (NVO) reported third-quarter sales of 79.2 billion Danish kroner ($11.9 billion), surpassing FactSet estimates of 73.6 billion kroner. Sales grew 4% year-on-year at constant exchange rates. Adjusted operating profit came in at 31.7 billion kroner, ahead of the expected 28.6 billion kroner.
The company upgraded its full-year outlook, now expecting adjusted revenue and operating profit growth between negative 2% and 2% on a constant currency basis. This is more optimistic than its earlier range of negative 6% to flat, which it revised upward in August. Strong sales of its Wegovy weight-loss pill at 5.4 billion kroner exceeded analyst expectations of about 4.5 billion kroner. Additional sales from injectable Wegovy and diabetes drug Ozempic also beat estimates, at 20.4 billion kroner and 29.7 billion kroner respectively.
Novo is competing closely with Eli Lilly in the GLP-1 weight-loss drug market, where investor focus remains on next-generation treatments addressing obesity-linked diseases. The company also announced planned CFO Karsten Munk Knudsen’s departure at the end of 2026, with Luigi La Corte from Galderma named as his successor. Investors will watch how the improved sales momentum and outlook revisions might affect annual revenue and profit growth forecasts.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Our take
Opinion from the Newsstocks AI desk, not investment adviceThe earnings report suggests Novo Nordisk is regaining momentum in the competitive GLP-1 market after a challenging period. The upgraded outlook and sales beat reflect strength in its drug portfolio, particularly Wegovy. However, competition remains a challenge. The trajectory of next-generation drug development and sales will be key to sustaining growth.
Key numbers
- Year-on-year sales growth
- 4%
- Adjusted operating profit
- 31.7 billion kroner
- Wegovy pill sales
- 5.4 billion kroner
What could help
- Stronger-than-expected Wegovy sales indicate growing market acceptance.
- Improved full-year revenue and profit guidance narrows previous downside risks.
What could hurt
- Intense competition from Eli Lilly and others could pressure market share and margins.
What to watch next
Investors will monitor annual revenue and profit growth progress based on updated forecasts and competitive dynamics in the GLP-1 market.
The background
Companies release quarterly earnings to report sales and profits, which investors use to assess business performance. Raising outlooks usually signals confidence in future growth.
Questions readers ask
Why did Novo Nordisk raise its full-year outlook?
Novo Nordisk raised its outlook due to better-than-expected third-quarter sales of 79.2 billion Danish kroner ($11.9 billion) and strong performance of its Wegovy pill.
Who will succeed Novo Nordisk's CFO Karsten Munk Knudsen?
Luigi La Corte, currently CFO of Galderma, will succeed Karsten Munk Knudsen at the end of 2026.
Understand this kind of story
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
